Home > Signaling Pathways>Neuronal Signaling>Dopamine Receptor >Cariprazine
Cariprazine

This product is for research use only, not for human use. We do not sell to patients.

Cariprazine
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
250mg$450Check With Us
500mg$750Check With Us
1g$1125Check With Us
email: [email protected]        [email protected]

Cat #: V3673 CAS #: 839712-12-8 Purity ≥ 98%

Description: Cariprazine (formerly known as MP-214 and RGH-188; Vraylar; Reagila) is a novel and potent antipsychotic drug that has been approved for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the treatment of major depressive disorders.

References: Seneca N, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011 Dec;218(3):579-8

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)463.87 (HCl salt)
Molecular FormulaC21H32Cl2N4O
CAS No.839712-12-8
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 10 mM in DMSOr
Water: <1 mg/mLr
Ethanol: <1 mg/mL
SMILES CodeO=C(N[C@H]1CC[C@H](CCN2CCN(C3=CC=CC(Cl)=C3Cl)CC2)CC1)N(C)C
SynonymsMP-214; MP 214; MP214; GH-188; RGH188; RGH 188; Cariprazine; Brand name: Vraylar
ProtocolIn VivoAdministration of Cariprazine (30 µg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements. Cariprazine has negligible effect on the time-activity curves in the cerebellum. At doses of 5.0 and 30 µg/kg, Cariprazine causes a dose-dependent dopamine D2/D3 receptor occupancy of ~45% and ~80% for both antagonist [11C] raclopride and agonist radioligand [11C]MNPA. Receptor occupancy of dopamine D2/D3 receptors calculated using the transient equilibrium and the MRTM2 methods ranged from 5% at the lowest dose (1.0 µg/kg) to 94% at the highest dose (300 µg/kg)
These protocols are for reference only. InvivoChem does not independently validate these methods.
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.